Proteomic signatures for identification of impaired glucose tolerance
J Carrasco-Zanini, M Pietzner, JV Lindbohm… - Nature medicine, 2022 - nature.com
The implementation of recommendations for type 2 diabetes (T2D) screening and diagnosis
focuses on the measurement of glycated hemoglobin (HbA1c) and fasting glucose. This …
focuses on the measurement of glycated hemoglobin (HbA1c) and fasting glucose. This …
BALDR: A Web-based platform for informed comparison and prioritization of biomarker candidates for type 2 diabetes mellitus
AT Lundgaard, F Burdet, T Siggaard… - PLoS Computational …, 2023 - journals.plos.org
Novel biomarkers are key to addressing the ongoing pandemic of type 2 diabetes mellitus.
While new technologies have improved the potential of identifying such biomarkers, at the …
While new technologies have improved the potential of identifying such biomarkers, at the …
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
A Wretlind, EH Zobel, A de Zawadzki… - Frontiers in Clinical …, 2022 - frontiersin.org
Background Liraglutide is a glucose-lowering medication used to treat type 2 diabetes and
obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the …
obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the …
Economic evaluations of precision medicine: case studies in diabetes
S Emamipour - 2023 - research.rug.nl
This thesis addressed the growing challenge of diabetes by exploring the cost-effectiveness
of precision medicine interventions. Diabetes varies greatly among individuals, making …
of precision medicine interventions. Diabetes varies greatly among individuals, making …